JP2015524443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524443A5 JP2015524443A5 JP2015525621A JP2015525621A JP2015524443A5 JP 2015524443 A5 JP2015524443 A5 JP 2015524443A5 JP 2015525621 A JP2015525621 A JP 2015525621A JP 2015525621 A JP2015525621 A JP 2015525621A JP 2015524443 A5 JP2015524443 A5 JP 2015524443A5
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- methyl
- carbamate
- tetrahydropyridin
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 device Substances 0.000 claims 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 29
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 230000009424 thromboembolic effect Effects 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010014513 Embolism arterial Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010037437 Pulmonary thrombosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000005242 cardiac chamber Anatomy 0.000 claims 1
- 208000002528 coronary thrombosis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- 230000003836 peripheral circulation Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 201000005060 thrombophlebitis Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 0 Cc1cnc(*)c(C)c1 Chemical compound Cc1cnc(*)c(C)c1 0.000 description 10
- LTUJJGBXVUBJAT-HJWRWDBZSA-N CC(C)=C/C(/C)=N\C=C Chemical compound CC(C)=C/C(/C)=N\C=C LTUJJGBXVUBJAT-HJWRWDBZSA-N 0.000 description 1
- FSPIBFKGESGOLU-UHFFFAOYSA-N CC(C=C(C)N1)=CC1=O Chemical compound CC(C=C(C)N1)=CC1=O FSPIBFKGESGOLU-UHFFFAOYSA-N 0.000 description 1
- JYYNAJVZFGKDEQ-UHFFFAOYSA-N Cc1ccnc(C)c1 Chemical compound Cc1ccnc(C)c1 JYYNAJVZFGKDEQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679197P | 2012-08-03 | 2012-08-03 | |
| US61/679,197 | 2012-08-03 | ||
| US201361786992P | 2013-03-15 | 2013-03-15 | |
| US61/786,992 | 2013-03-15 | ||
| PCT/US2013/053414 WO2014022766A1 (en) | 2012-08-03 | 2013-08-02 | Dihydropyridone p1 as factor xia inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524443A JP2015524443A (ja) | 2015-08-24 |
| JP2015524443A5 true JP2015524443A5 (enExample) | 2016-04-14 |
| JP6082462B2 JP6082462B2 (ja) | 2017-02-15 |
Family
ID=48949289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525621A Active JP6082462B2 (ja) | 2012-08-03 | 2013-08-02 | 第ｘｉａ因子阻害剤としてのジヒドロピリドンｐ１ |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9376444B2 (enExample) |
| EP (1) | EP2882734B1 (enExample) |
| JP (1) | JP6082462B2 (enExample) |
| KR (1) | KR20150038369A (enExample) |
| AR (1) | AR093759A1 (enExample) |
| AU (1) | AU2013296258A1 (enExample) |
| BR (1) | BR112015002293A2 (enExample) |
| CA (1) | CA2880898A1 (enExample) |
| CY (1) | CY1118450T1 (enExample) |
| DK (1) | DK2882734T3 (enExample) |
| EA (1) | EA025392B1 (enExample) |
| ES (1) | ES2605824T3 (enExample) |
| HR (1) | HRP20161378T1 (enExample) |
| HU (1) | HUE031582T2 (enExample) |
| IL (1) | IL237012A0 (enExample) |
| LT (1) | LT2882734T (enExample) |
| MX (1) | MX361370B (enExample) |
| PL (1) | PL2882734T3 (enExample) |
| PT (1) | PT2882734T (enExample) |
| RS (1) | RS55581B1 (enExample) |
| SG (1) | SG11201500270RA (enExample) |
| SI (1) | SI2882734T1 (enExample) |
| SM (2) | SMT201700003T1 (enExample) |
| TW (1) | TW201410666A (enExample) |
| UY (1) | UY34959A (enExample) |
| WO (1) | WO2014022766A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| WO2013056034A1 (en) | 2011-10-14 | 2013-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| SI2766346T1 (sl) | 2011-10-14 | 2017-05-31 | Bristol-Myers Squibb Company | Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji |
| EP2899183B1 (en) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors |
| US9315519B2 (en) | 2012-10-12 | 2016-04-19 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
| EP2906551B1 (en) | 2012-10-12 | 2018-02-28 | Bristol-Myers Squibb Company | Crystalline forms of a factor xia inhibitor |
| WO2014059214A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| KR20240017118A (ko) * | 2014-01-31 | 2024-02-06 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제제로서의 헤테로시클릭 P2' 기를 갖는 마크로사이클 |
| NO2760821T3 (enExample) * | 2014-01-31 | 2018-03-10 | ||
| EP3104701B1 (en) | 2014-02-11 | 2019-01-30 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| WO2015123093A1 (en) * | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| EP3189047B1 (en) * | 2014-09-04 | 2018-12-26 | Bristol-Myers Squibb Company | Diamide macrocycles that are fxia inhibitors |
| NO2721243T3 (enExample) | 2014-10-01 | 2018-10-20 | ||
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| JP6742348B2 (ja) | 2015-06-19 | 2020-08-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としてのジアミド大員環 |
| JP6629958B2 (ja) | 2015-07-29 | 2020-01-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アルキルまたはシクロアルキルＰ２’基を担持する大員環の第ＸＩａ因子阻害剤 |
| US10676477B2 (en) | 2015-07-29 | 2020-06-09 | Bristol-Myers Squibb Company | Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group |
| MX387515B (es) * | 2015-10-29 | 2025-03-18 | Merck Sharp & Dohme Llc | Inhibidores de factor xia. |
| EP3371162B1 (en) * | 2015-10-29 | 2022-01-26 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use |
| WO2017151746A1 (en) * | 2016-03-02 | 2017-09-08 | Bristol-Myers Squibb Company | Diamide macrocycles having factor xia inhibiting activity |
| EP3500556B1 (en) | 2016-08-22 | 2023-08-02 | Merck Sharp & Dohme LLC | Pyridine-1-oxide derivatives and their use as factor xia inhibitors |
| US12018027B2 (en) | 2019-04-16 | 2024-06-25 | China Resources Biopharmaceutical Company Limited | Macrocyclic derivatives acting as XIa factor inhibitor |
| JP7286001B2 (ja) * | 2019-07-23 | 2023-06-02 | メッドシャイン ディスカバリー インコーポレイテッド | 第ＸＩａ因子阻害剤としての大環状誘導体 |
| JP2023535815A (ja) * | 2020-07-29 | 2023-08-21 | シャンハイ キュアジーン ファーマシューティカル カンパニー，リミテッド | 抗血小板薬およびその使用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| WO2000077027A2 (en) | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| EP1427415B1 (en) | 2001-09-21 | 2009-08-12 | Brystol-Myers Squibb Company | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| JP5236293B2 (ja) | 2005-01-13 | 2013-07-17 | ブリストル−マイヤーズ スクイブ カンパニー | Ｘｉａ因子阻害剤としての置換ビアリール化合物 |
| US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
| EP1981854B1 (en) | 2005-12-14 | 2011-06-01 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| US8466295B2 (en) | 2005-12-14 | 2013-06-18 | Bristol-Myers Squibb Company | Thiophene derivatives as factor XIa inhibitors |
| AU2006325746A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| EP2102189B1 (en) | 2006-12-15 | 2015-07-29 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| PE20081775A1 (es) * | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
| EP2152664B1 (en) | 2007-06-13 | 2014-09-03 | Bristol-Myers Squibb Company | Dipeptide analogs as coagulation factor inhibitors |
| EP2265601B1 (en) | 2008-03-13 | 2012-02-01 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| CA2789622C (en) | 2010-02-11 | 2018-04-03 | Bristol-Myers Squibb Company | Macrocycles as factor xia inhibitors |
| TW201319068A (zh) * | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| SI2766346T1 (sl) | 2011-10-14 | 2017-05-31 | Bristol-Myers Squibb Company | Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji |
| WO2013056034A1 (en) | 2011-10-14 | 2013-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2899183B1 (en) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors |
| DK2794597T3 (en) | 2011-12-21 | 2018-01-15 | Ono Pharmaceutical Co | PYRIDINON AND PYRIMIDINON DERIVATIVES AS FACTOR XIA INHIBITORS |
| JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | ３位置換プロリン誘導体 |
| GB201209138D0 (en) | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
-
2013
- 2013-08-02 LT LTEP13747624.8T patent/LT2882734T/lt unknown
- 2013-08-02 MX MX2015000919A patent/MX361370B/es active IP Right Grant
- 2013-08-02 RS RS20170019A patent/RS55581B1/sr unknown
- 2013-08-02 UY UY0001034959A patent/UY34959A/es unknown
- 2013-08-02 TW TW102127904A patent/TW201410666A/zh unknown
- 2013-08-02 EA EA201590284A patent/EA025392B1/ru not_active IP Right Cessation
- 2013-08-02 AR ARP130102762A patent/AR093759A1/es unknown
- 2013-08-02 AU AU2013296258A patent/AU2013296258A1/en not_active Abandoned
- 2013-08-02 EP EP13747624.8A patent/EP2882734B1/en active Active
- 2013-08-02 SI SI201330344A patent/SI2882734T1/sl unknown
- 2013-08-02 US US14/419,014 patent/US9376444B2/en active Active
- 2013-08-02 SG SG11201500270RA patent/SG11201500270RA/en unknown
- 2013-08-02 CA CA2880898A patent/CA2880898A1/en not_active Abandoned
- 2013-08-02 JP JP2015525621A patent/JP6082462B2/ja active Active
- 2013-08-02 KR KR20157004959A patent/KR20150038369A/ko not_active Withdrawn
- 2013-08-02 WO PCT/US2013/053414 patent/WO2014022766A1/en not_active Ceased
- 2013-08-02 PL PL13747624T patent/PL2882734T3/pl unknown
- 2013-08-02 PT PT137476248T patent/PT2882734T/pt unknown
- 2013-08-02 HR HRP20161378TT patent/HRP20161378T1/hr unknown
- 2013-08-02 DK DK13747624.8T patent/DK2882734T3/en active
- 2013-08-02 US US13/957,609 patent/US20140038969A1/en not_active Abandoned
- 2013-08-02 HU HUE13747624A patent/HUE031582T2/en unknown
- 2013-08-02 SM SM20170003T patent/SMT201700003T1/it unknown
- 2013-08-02 ES ES13747624.8T patent/ES2605824T3/es active Active
- 2013-08-02 BR BR112015002293A patent/BR112015002293A2/pt not_active Application Discontinuation
-
2015
- 2015-01-29 IL IL237012A patent/IL237012A0/en unknown
-
2017
- 2017-01-04 SM SM201700003T patent/SMT201700003B/it unknown
- 2017-01-10 CY CY20171100026T patent/CY1118450T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161378T1 (hr) | Dihidropiridon kao faktor xia inhibitora | |
| JP2021138755A5 (enExample) | ||
| JP2017504640A5 (enExample) | ||
| JP2017504642A5 (enExample) | ||
| JP2021088610A5 (enExample) | ||
| JP2022510313A5 (enExample) | ||
| JP2009536218A5 (enExample) | ||
| JP2015508749A5 (enExample) | ||
| JP2021516240A5 (enExample) | ||
| JP2023529354A5 (enExample) | ||
| HRP20171950T1 (hr) | Pirimidinoni kao inhibitori faktora xia | |
| JP2017517512A5 (enExample) | ||
| JP2016516699A5 (enExample) | ||
| JP2017505790A5 (enExample) | ||
| JP2004534825A5 (enExample) | ||
| JP2019527215A5 (enExample) | ||
| JP2015051983A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2016523923A5 (enExample) | ||
| JP2013523733A5 (enExample) | ||
| RU2014152276A (ru) | Замещенные пирролидины в качестве ингибиторов фактора xia для лечения тромбоэмболических заболеваний | |
| JP2020523327A5 (enExample) | ||
| JP2015164972A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 |